In the vitamin category, private label leads the one- and two-letter segment, with $425 million in annual dollar sales, according to the latest Promo Watch report from Drug Store News, Competitive Promotion Report and IRI.
Reuters is reporting that AstraZeneca will be acquiring Takeda Pharmaceuticals’ respiratory business for $575 million, a deal that includes expanded rights to COPD treatment roflumilast, which AstraZeneca has marketed as Daliresp in the United States since earlier this year. “Full acquisition of the global rights will support AstraZeneca's respiratory franchise and complement the company's portfolio of treatments for severe COPD,” the company said. (Reuters)
The New York Times is reporting that Turing Pharmaceuticals CEO Martin Shkreli has been arrested on charges of securities fraud from when he ran bio Retrophin and his time managing hedge funds. Shkreli has been in the press recently for his actions as Turing CEO — raising the price of Daraprim from 13.50 per pill to $750 per pill. (New York Times)
Under a potential deal, Boehringer Ingelheim would take over Sanofi’s animal health business Merial, and Sanofi would receive Boehringer Ingelheim’s consumer healthcare business (excepting China), making it one of the world's largest OTC makers.